Oncology
Niraparib (PARP inhibitor)
Ovarian Cancer (1st line maintenance)¹
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Mainland China, HK & Macau Ovarian Cancer (Platinum sensitive relapsed maintenance)¹
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Mainland China, HK & Macau Tumor Treating Fields
Glioblastoma (GBM)²
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Greater China Non-Small Cell Lung Cancer (NSCLC) (2nd line+)
Phase 3 / Pivotal:
Ongoing or Completed
APPROVED:
USACOMMERCIAL TERRITORIES:
Greater China Brain Metastases from NSCLC
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Pancreatic Cancer (1st line)
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Ripretinib (TKI)
Gastrointestinal Stromal Tumors (GIST) (4th line)
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Greater China Repotrectinib (ROS1, TRK)
ROS1+ NSCLC
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Greater China NTRK+ solid tumors
Phase 3 / Pivotal:
Ongoing or Completed
APPROVED:
USACOMMERCIAL TERRITORIES:
Greater China Tisotumab vedotin (TF ADC)
Cervical Cancer (2nd line+ r/m)
Phase 3 / Pivotal:
Ongoing or Completed
APPROVED:
USACOMMERCIAL TERRITORIES:
Greater China Cervical Cancer (1st line r/m, combo)³*
Phase 2 / Poc:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Bemarituzumab (FGFR2b)
Gastric/GEJ Cancer (1st line)
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China ZL-1218 (CCR8)
Solid Tumors
Phase 1:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Global ZL-1310 (DLL3 ADC)
ES-SCLC
Phase 1:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Global Other NECs
Pre-clinical:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Global ZL-6301 (ROR1 ADC)
Solid Tumors
Pre-clinical:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Global ZL-6201 (LRRC15 ADC)
Solid Tumors
Pre-clinical:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Global Immunology
Efgartigimod (FcRn)
Generalized Myasthenia Gravis (gMG)
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Greater China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Greater China Thyroid Eye Disease (TED)
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Myositis
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Seronegative gMG*
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Ocular MG*
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Sjogren’s Disease*
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China LN
Phase 2 / Poc:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Povetacicept (BAFF/APRIL)
IgA Nephropathy
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China and Singapore⁴ ZL-1108 (IGF-1R)
TED*
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China ZL-1102 (IL-17)
Mild-to-Moderate Chronic Plaque Psoriasis
Phase 2 / Poc:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Global ZL-1503 (IL13/IL31R)
Mod-to-Sev AD
Pre-clinical:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Global Neuroscience
Xanomeline-Trospium (KarXT)
Schizophrenia
Phase 3 / Pivotal:
Ongoing or Completed
REGISTRATION:
Mainland ChinaAPPROVED:
USACOMMERCIAL TERRITORIES:
Greater China Psychosis associated with Alzheimer’s Disease (ADP)
Phase 3 / Pivotal:
Ongoing or Completed
COMMERCIAL TERRITORIES:
Greater China Infectious Disease
Omadacycline
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Greater China Community-Acquired Bacterial Pneumonia (CABP)
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Greater China Sulbactam-Durlobactam
HABP/VABP caused by Acinetobacter Baumannii-calcoaceticus Complex (ABC)
APPROVED:
USAMainland China
COMMERCIAL TERRITORIES:
Asia Pacific⁵ Notes: The trademarks and registered trademarks within are the property of their respective owners. *Greater China trial in preparation or under planning. Greater China = mainland China, Hong Kong, Macau and Taiwan, collectively. (1) Also launched in Hong Kong and Macau; (2) Commercially available in Hong Kong; (3) Combination with carboplatin and KEYTRUDA +/- bevacizumab; (4) Zai Lab has exclusive license to develop and commercialize of povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore; (5) Zai Lab has exclusive license to develop and commercialize SUL-DUR in mainland China, Hong Kong, Taiwan, Macau, Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand, and Japan.
Ongoing Clinical Trials
For more information about the above trials, please visit https://clinicaltrials.gov